top of page

Biopharma Daily Stock Updates - 03/07/22

$XBI $83.76 | -0.17%


Covid Updates

Pipeline Updates

$LVTX +1.4% LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022. source

$ALPN -8.9% Alpine Immune Sciences Reports FDA Partial Clinical Hold on NEON-2 Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab. source

$HZNP -0.7% Horizon Therapeutics plc Announces FDA Has Granted Priority Review of the Supplemental Biologics License Application (sBLA) for the Concomitant Use of KRYSTEXXA® (pegloticase injection) Plus Methotrexate for People Living With Uncontrolled Gout. source

$HARP +12.4% Harpoon Therapeutics Granted Orphan Drug Designation for HPN328 for Treatment of Small Cell Lung Cancer. source

$OPTN +1.1% Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis. source

$TNXP -3.3% Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Evaluate TNX-1900 (Intranasal Potentiated Oxytocin) for Treating Binge Eating Disorder. source

$AGEN +0.3% Targovax ASA and Agenus announce collaboration on mutant KRAS cancer vaccine adjuvanted with QS-21 STIMULON™. source

$KALV +0.8% KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical Trial. source

$SPPI +10.8% Spectrum Pharmaceuticals Presents Positive Data for Poziotinib in First-line NSCLC Patients with HER2 Exon 20 Insertion Mutations. source

$KNTE +1.9% Kinnate Biopharma Inc. Presents Data from its Real-World Clinico-Genomic Study Collaboration with Tempus at the Virtual ESMO Targeted Anticancer Therapies Congress. source

$EVLO +3.3% Evelo Biosciences to Host KOL Discussion on Treatment Advances for All Stages of Psoriasis and Potential of SINTAX Medicines. source

Business Updates

$MRNA -7.3% Moderna Announces Memorandum of Understanding with the Government of the Republic of Kenya to Establish its First mRNA Manufacturing Facility in Africa. source

$TXMD +43.1% TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx. source

$HCM -13.3% HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer. source


Posted by FS/JM

bottom of page